Testing a new method for detecting certain bacteria in lung infections
Part of Infections, Lungs & breathing clinical trials.
This study checks if a special test (Xpert Carba-R) can find a type of drug-resistant bacteria, called CRE, in fluid from the lungs and in rectal swabs. It might help doctors treat lower respiratory tract infections more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a type of bacteria called CRKP in your lower respiratory tract (like sputum or BAL fluid) within the last 15 days.
- You have a lower respiratory tract infection shown by at least two of these: fever over 100.7°F or below 97.7°F, high or low white blood cell count (more than 10,000 or less than 4,000), or thick, yellowish mucus from your airways.
- You do not have other bacteria that can make certain antibiotics stop working in your lower respiratory tract.
- You have never had an infection with CRE before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to screen patients for CPE bacteria when they are admitted to the hospital. The goal is to find colonized patients early and help reduce the spread of antibiotic resistance.
This trial tests a medicine called colistimethate sodium for people in the hospital with a serious infection (pneumonia or bloodstream infection) caused by a resistant bacteria called CRE. The goal is to see if this antibiotic can effectively treat the infection.
This trial tests a new imaging method to quickly find Pseudomonas aeruginosa bacteria in lung fluid, and then see how well treatment works. It aims to help doctors diagnose and treat this tough infection faster.
This trial tests a new rapid test and infection prevention plan for patients who may carry carbapenem-resistant bacteria (CPE) in the hospital. It aims to see if faster detection and better infection control can reduce the spread of these hard-to-treat germs.
This trial tests whether a treatment called fecal microbiota transplantation (giving you a capsule of healthy bacteria from a donor) can help clear a hard-to-treat bacteria called CRE from your body. It may help prevent future infections and reduce the need for strong antibiotics.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Hear when a new Carbapenem-Resistant Enterobacteriaceae trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.